Shionogi & Co., Ltd. (SGIOF) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Drug Manufacturers - Specialty & Generic industria. La empresa tiene su sede en Osaka, Japan. El CEO actual es Isao Teshirogi.
SGIOF tiene fecha de IPO 2018-02-28, 4,955 empleados a tiempo completo, cotiza en el Other OTC, una capitalización de mercado de $18.59B.
Shionogi & Co., Ltd. is a Japanese pharmaceutical company founded in 1878 and headquartered in Osaka that engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices. The company's marketed products include Fetroja for multidrug-resistant gram-negative bacterial infections, Xofluza for influenza, and Tivicay for HIV treatment. Shionogi maintains a substantial pipeline of drug candidates across multiple therapeutic areas including infectious diseases, oncology, central nervous system disorders, and rare diseases, with notable programs in obesity, depression, neuropathic pain, and COVID-19 treatments. The company also collaborates with leading academic institutions including Nagasaki University and the National Institute of Infectious Diseases on antimalarial drug development initiatives.
